South Korea to host production of 150M Sputnik V doses for global distribution
Singapore, Nov. 13 -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), and GL Rapha, one of the leading South Korean bio-tech companies (including the subsidiary Hankook Korus Pharm) have agreed to produce over 150 million doses per year of the world's first registered vaccine against the novel coronavirus infection - Sputnik V.
The parties intend to commence production in December 2020 and a rollout of the Sputnik V vaccine in January 2021. RDIF and GL Rapha will supply over 150 million doses per year produced in South Korea for global distribution.
The first interim analysis of The Sputnik V vaccine data of Phase III clinical trials in Russia has demonstrated 92% efficacy against coronavirus based on 20 confi...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.